The FDA has approved Raloxifene as a treatment to reduce breast cancer risk in menopausal women. Raloxifene, under the brand name Evista, has previously been approved for postmenopausal women with osteoporosis but is now available to women with high risk for invasive breast cancer. Based on clinical studies of postmenopausal women over a 10 year period of time, raloxifene "provides an important new option for women at heightened risk of breast cancer," said Dr. Steven Galson, director of the FDA's Center for Drug Evaluation and Research.
Raloxifene, manufactured by Eli Lilly & Co.(NYSE:LLY) is a drug known as a selective estrogen receptor modulator (SERM). It block seems to block estrogen receptors in the breast thus reducing the risk of invasive breast cancer. The side effects are severe and can include blood clots, hot flashes, leg cramps, flu-like symptoms, joint pain and sweating.
Invasive breast cancer accounts for more the 25% of cancers in women and the American Cancer Society estimates that over 178,000 women will be diagnosed with it this year.
Raloxifene, manufactured by Eli Lilly & Co.(NYSE:LLY) is a drug known as a selective estrogen receptor modulator (SERM). It block seems to block estrogen receptors in the breast thus reducing the risk of invasive breast cancer. The side effects are severe and can include blood clots, hot flashes, leg cramps, flu-like symptoms, joint pain and sweating. 
.jpg)
Comment Preview